Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in determination of prostate cancer and importance of prostate volume

Ceylan, Cavit; Doluoğlu, Ömer Gökhan; Aglamis, Erdogan; Baytok, Ozkan

doi:10.5489/cuaj.510

Cited by 16 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference may be caused by differences in prostate volume (mean 44.82 vs. 31.9 ml) and serum PSA level (mean 9.73 vs. 8.58 ng/ml) between the two studies. Previous studies have identified patient subgroups with high positive rates in repeat biopsy; there are high false negative rates in patients with a large prostate volume and elevated serum PSA levels ( 20 , 28 ).…”

Section: Discussionmentioning

confidence: 99%

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

Chen¹,

Yi²,

Jiang³

et al. 2014

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The detection rate of prostate cancer (PCa) using traditional biopsy guided by transrectal ultrasound (TRUS) is not satisfactory. The aim of this study was to determine the utility of 3-Tesla (3-T) magnetic resonance imaging (MRI) prior to TRUS-guided prostate biopsy and to investigate which subgroup of patients had the most evident improvement in PCa detection rate. A total of 420 patients underwent 3-T MRI examination prior to the first prostate biopsy and the positions of suspicious areas were recorded respectively. TRUS-guided biopsy regimes included systematic 12-core biopsy and targeted biopsy identified by MRI. Patients were divided into subgroups according to their serum prostate-specific antigen (PSA) levels, PSA density (PSAD), prostate volume, TRUS findings and digital rectal examination (DRE) findings. The ability of MRI to improve the cancer detection rate was evaluated. The biopsy positive rate of PCa was 41.2% (173/420), and 41 of the 173 (23.7%) patients were detected only by targeted biopsy in the MRI-suspicious area. Compared with the systematic biopsy, the positive rate was significantly improved by the additional targeted biopsy (P=0.0033). The highest improvement of detection rate was observed in patients with a PSA level of 4–10 ng/ml, PSAD of 0.12–0.20 ng/ml2, prostate volume >50 ml, negative TRUS findings and negative DRE findings (P<0.05). Therefore, it is considered that 3-T MRI examination could improve the PCa detection rate on first biopsy, particularly in patients with a PSA level of 4–10 ng/ml, PSAD of 0.12–0.20 ng/ml2, prostate volume of >50 ml, negative TRUS findings and negative DRE findings.

show abstract

Section: Discussionmentioning

confidence: 99%

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

Chen¹,

Yi²,

Jiang³

et al. 2014

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Despite efforts made to identify new serum and biological markers and refinement of imaging modalities for the diagnosis of PCa, prostate biopsy performed with the guidance of TRUS is still the most important diagnostic method (8). In order to increase the cancer detection rate of prostate biopsy, various schemes have been applied in time such as sextant biopsy, extended biopsy and saturation biopsy (9). Treatment of patients, who are diagnosed not to have cancer in the first prostate biopsy despite persistently elevated levels of PSA, is a common problem for the urologist.…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of Core Lenght in Saturation Prostate Biopsy

Yücel¹,

Budak²

2018

jus

View full text Add to dashboard Cite

Objective: To investigate the effect of core length on cancer detection in saturation prostate biopsy. We hypothesized that increasing mean and total core length in saturation prostate biopsy may allow more tissue sampling, thus, may increase the prostate cancer detection rate. Materials and Methods: We retrospectively analyzed medical records of 145 patients who underwent 24-core transrectal ultrasound-guided saturation biopsy at our institution. We evaluated the clinopathological factors, including age, prostate specific antigen (PSA), prostate volume, mean core length and the total biopsy core length. The patients were divided into 3 groups according to their total biopsy core length; group 1: <20 cm, group 2: 20-30 cm and group 3: >30 cm. These groups were compared according to age, PSA value, prostate volume and cancer detection rate. Results: The mean age, core length and total core length were 62.4±7.0 years, 10.91±1.8 mm, and 26.2±4.7 cm, respectively. The overall cancer detection rate was 33.8%. There was no statistically significant difference in mean core length and total core length between patients diagnosed with prostate cancer and those without it. The cancer detection rates in group 1, 2 and 3 were 25%, 37.4% and 23.1%, respectively. When these 3 groups were compared with each other, group 2 had a statistically significantly higher cancer detection rate relative to group 1 (p=0.001). Multivariate analysis showed no statistically difference in cancer detection rate between the groups (p=0.302). Conclusion: Mean and total core length may not have any significant effect on prostate cancer detection in patients undergoing saturation prostate biopsy.

show abstract

“…The indication for biopsy was the presence of prostatic nodules detected on DRE, which indicated that this type of examination may reveal tumors in men with a low PSA level [3]. In other studies also, no statistically significant differences were found between PSA levels by the number of cores [15,16,18]. …”

Section: Discussionmentioning

confidence: 99%

What Is the Ideal Core Number for Ultrasound-Guided Prostate Biopsy?

et al. 2014

View full text Add to dashboard Cite

PurposeWe evaluated the utility of 10-, 12-, and 16-core prostate biopsies for detecting prostate cancer (PCa) and correlated the results with prostate-specific antigen (PSA) levels, prostate volumes, Gleason scores, and detection rates of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP).Materials and MethodsA prospective controlled study was conducted in 354 consecutive patients with various indications for prostate biopsy. Sixteen-core biopsy specimens were obtained from 351 patients. The first 10-core biopsy specimens were obtained bilaterally from the base, middle third, apex, medial, and latero-lateral regions. Afterward, six additional punctures were performed bilaterally in the areas more lateral to the base, middle third, and apex regions, yielding a total of 16-core biopsy specimens. The detection rate of carcinoma in the initial 10-core specimens was compared with that in the 12- and 16-core specimens.ResultsNo significant differences in the cancer detection rate were found between the three biopsy protocols. PCa was found in 102 patients (29.06%) using the 10-core protocol, in 99 patients (28.21%) using the 12-core protocol, and in 107 patients (30.48%) using the 16-core protocol (p=0.798). The 10-, 12-, and 16-core protocols were compared with stratified PSA levels, stratified prostate volumes, Gleason scores, and detection rates of HGPIN and ASAP; no significant differences were found.ConclusionsCancer positivity with the 10-core protocol was not significantly different from that with the 12- and 16-core protocols, which indicates that the 10-core protocol is acceptable for performing a first biopsy.

show abstract

Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in determination of prostate cancer and importance of prostate volume

Cited by 16 publications

References 29 publications

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy

Clinical Value of Core Lenght in Saturation Prostate Biopsy

What Is the Ideal Core Number for Ultrasound-Guided Prostate Biopsy?

Contact Info

Product

Resources

About